Linklaters advises PAI Partners on the sale of Atos Medical to Coloplast

Linklaters has advised PAI Partners, a pre-eminent private equity firm, on the sale of Swedish headquartered Atos Medical, a global market leader in supporting patients with a neck stoma, to Coloplast, a Danish multinational company that develops, manufactures, and markets medical devices for an enterprise value of cEUR2.2 billion.

The Linklaters’ cross-border team was led by Corporate partners Rasmus Kindlund (Stockholm), Mike Bienenfeld (London), and Fredrik Lindqvist (Stockholm). They were supported by Counsel Cole Smith (London), managing associates Nima Naderi (Stockholm), Daniel Bergman (London) and Ina Lunneryd (Brussels); and associates Sophia Astberg (Stockholm), Alex Reed (London), Erica Wesström (Stockholm), Thyra Taune (Stockholm) and Erik Samuelsson (Stockholm).

Linklaters has supported PAI Partners throughout their journey with Atos Medical, from acquiring the company in 2016 to supporting their recent exit. Under its ownership, Atos Medical has developed into a global leader in supporting all patients with a neck stoma. The sale of Atos Medical to industry leader Coloplast will further strengthen the company’s reach and influence. Closing of the transaction is subject to customary regulatory approvals and is anticipated in Q1 2022.

This is the latest high-profile healthcare deal for Linklaters following its role advising STADA on the acquisition of a European consumer healthcare portfolio of 16 brands from Sanofi in July 2021, Apax Partners on its acquisition of Rodenstock Group, a leading manufacturer of premium ophthalmic lenses, from Compass Partners in April 2021 and advising Partners Group, as majority shareholder, on its entry into exclusive negotiations with EQT Private Equity relating to the disposal of Cerba HealthCare in March 2021.